RPTX Repare Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RPTX

Price (delayed)

$3.46

Market cap

$145.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.23

Enterprise value

$38.09M

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled ...

Highlights
RPTX's debt is down by 37% year-on-year and by 13% since the previous quarter
RPTX's quick ratio is up by 32% year-on-year and by 13% since the previous quarter
Repare Therapeutics's gross profit has plunged by 61% YoY and by 9% from the previous quarter
Repare Therapeutics's revenue has plunged by 61% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://reparerx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RPTX
Market
Shares outstanding
42.18M
Market cap
$145.95M
Enterprise value
$38.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
2.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.74
Earnings
Revenue
$51.13M
EBIT
-$103.18M
EBITDA
-$99.03M
Free cash flow
-$129.1M
Per share
EPS
-$2.23
Free cash flow per share
-$3.07
Book value per share
$5.03
Revenue per share
$1.21
TBVPS
$6.03
Balance sheet
Total assets
$253.9M
Total liabilities
$41.82M
Debt
$3.41M
Equity
$212.08M
Working capital
$204.61M
Liquidity
Debt to equity
0.02
Current ratio
6.24
Quick ratio
5.84
Net debt/EBITDA
1.09
Margins
EBITDA margin
-193.7%
Gross margin
100%
Net margin
-183.4%
Operating margin
-227.3%
Efficiency
Return on assets
-31.8%
Return on equity
-39.8%
Return on invested capital
-79.8%
Return on capital employed
-48%
Return on sales
-201.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RPTX stock price

How has the Repare Therapeutics stock price performed over time
Intraday
3.28%
1 week
8.13%
1 month
-15.82%
1 year
-63.85%
YTD
-52.6%
QTD
-26.54%

Financial performance

How have Repare Therapeutics's revenue and profit performed over time
Revenue
$51.13M
Gross profit
$51.13M
Operating income
-$116.22M
Net income
-$93.8M
Gross margin
100%
Net margin
-183.4%
Repare Therapeutics's gross profit has plunged by 61% YoY and by 9% from the previous quarter
Repare Therapeutics's revenue has plunged by 61% YoY and by 9% from the previous quarter
Repare Therapeutics's operating margin has decreased by 22% QoQ
RPTX's operating income is down by 11% QoQ

Growth

What is Repare Therapeutics's growth rate over time

Valuation

What is Repare Therapeutics stock price valuation
P/E
N/A
P/B
0.69
P/S
2.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.74
RPTX's EPS is up by 3.5% from the previous quarter
The P/B is 63% below the last 4 quarters average of 1.8
The equity has contracted by 24% YoY and by 9% from the previous quarter
Repare Therapeutics's revenue has plunged by 61% YoY and by 9% from the previous quarter
The P/S is 47% lower than the last 4 quarters average of 5.2

Efficiency

How efficient is Repare Therapeutics business performance
RPTX's ROS is down by 24% from the previous quarter
Repare Therapeutics's ROIC has decreased by 18% from the previous quarter
The ROA has contracted by 5% from the previous quarter
RPTX's return on equity is down by 3.1% since the previous quarter

Dividends

What is RPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RPTX.

Financial health

How did Repare Therapeutics financials performed over time
Repare Therapeutics's total liabilities has shrunk by 51% YoY and by 21% QoQ
The current ratio rose by 39% YoY and by 11% QoQ
RPTX's debt is 98% smaller than its equity
RPTX's debt is down by 37% year-on-year and by 13% since the previous quarter
The equity has contracted by 24% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.